

ANNEXURE I

Krsnaa Diagnostics Limited

Scrip Code : 543328

Quarter Ending : March, 2023

i. Composition of Board of Director

Title	Name of the Director	Category	Initial Date of Appointment	Date of Appointment	Date of cessation	Tenure	No. of Directorship in listed entities including this listed entity	No of memberships in Audit/ Stakeholder Committee(s) including this listed entity	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity
Mr.	Rajendra Mutha	Executive Director, Chairperson	22-Dec-2010	26-Apr-2021		60	1	0	0
Ms.	Pallavi Bhatevara	Executive Director, MD	29-Jan-2013	26-Apr-2021		60	1	0	0
Mr.	Yash Mutha	Executive Director	31-Jan-2019	26-Apr-2021		60	1	2	0
Mr.	Prem Pradeep	Non-Executive – Nominee Director	08-Oct-2020	08-Oct-2020			1	1	0
Mr.	Chetan Desai	Non-Executive – Independent Director	25-Apr-2021	25-Apr-2021		60	5	8	5
Ms.	Chhaya Palrecha	Non-Executive – Independent Director	25-Apr-2021	25-Apr-2021		60	1	3	1
Mr.	Rajiva Ranjan Verma	Non-Executive – Independent Director	25-Apr-2021	25-Apr-2021		60	1	1	0
Mr.	Adesh Kumar Gupta	Non-Executive – Independent Director	28-May-2022	28-May-2022		60	6	9	3

ii. Composition of Committees

Audit Committee				
Sr. No.	Name of the Committee member	Category	Appointment Date	Cessation Date
1	Chetan Desai	Non-Executive - Independent Director, Chairperson	25-Apr-2021	
2	Chhaya Palrecha	Non-Executive - Independent Director, Member	25-Apr-2021	
3	Adesh Kumar Gupta	Non-Executive - Independent Director, Member	21-Jul-2022	
4	Rajiva Ranjan Verma	Non-Executive - Independent Director, Member	25-Apr-2021	
5	Yash Mutha	Executive Director, Member	31-Jan-2019	
6	Prem Pradeep	Non-Executive - Nominee Director, Member	25-Apr-2021	

Stakeholders Relationship Committee				
Sr. No.	Name of the Director	Category	Appointment Date	Cessation Date
1	Adesh Kumar Gupta	Non-Executive - Independent Director, Chairperson	21-Jul-2022	
3	Yash Mutha	Executive Director, Member	25-Apr-2021	
4	Chhaya Palrecha	Non-Executive - Independent Director, Member	31-Jan-2022	

Risk Management Committee				
Sr. No.	Name of the Director	Category	Appointment Date	Cessation Date
1	Rajiva Ranjan Verma	Non-Executive - Independent Director, Chairperson	25-Apr-2021	
2	Adesh Kumar Gupta	Non-Executive - Independent Director, Member	21-Jul-2022	
3	Yash Mutha	Executive, Member	25-Apr-2021	

Nomination and Remuneration Committee

<i>Sr. No.</i>	<i>Name of the Director</i>	<i>Category</i>	<i>Appointment Date</i>	<i>Cessation Date</i>
1	Adesh Kumar Gupta	Non-Executive - Independent Director,Chairperson	21-Jul-2022	
2	Chhaya Palrecha	Non-Executive - Independent Director, Member	25-Apr-2021	
3	Prem Pradeep	Non-Executive - Nominee Director,Member	25-Apr-2021	
4	Chetan Desai	Non-Executive - Independent Director, Member	31-Jan-2022	

Corporate Social Responsibility Committee

<i>Sr. No.</i>	<i>Name of the Director</i>	<i>Category</i>	<i>Appointment Date</i>	<i>Cessation Date</i>
1	Rajendra Mutha	Executive Director,Chairperson	26-Apr-2021	
2	Pallavi Bhatevara	Executive Director, Member	17-Jun-2019	
3	Prem Pradeep	Non-Executive - Nominee Director,Member	26-Apr-2021	
4	Rajiva Ranjan Verma	Non-Executive - Independent Director, Member	26-Apr-2021	

Operation Committee

<i>Sr. No.</i>	<i>Name of the Director</i>	<i>Category</i>	<i>Appointment Date</i>	<i>Cessation Date</i>
1	Rajendra Mutha	Executive Director,Chairperson	25-Mar-2023	
2	Pallavi Bhatevara	Executive Director, Member	25-Mar-2023	
3	Yash Mutha	Executive, Member	25-Mar-2023	

Meeting of Board of Directors					
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Whether requirement of Quorum met	Total Number of Directors as on date of the meeting	Number of Directors present (All directors including Independent Director)	Number of Independent Directors attending the meeting
09-Nov-2022	-	Yes	8	7	4
	13-Feb-2023	Yes	8	7	3
	25-Mar-2023	Yes	8	7	4
Maximum gap between any two consecutive (in number of days)		95			

Meeting of Committees							
Name of the Committee	Date(s) of meeting during of the committee in the previous quarter	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present (All directors including Independent Director)	Number of Independent Directors attending the meeting	No. of Members attending the meeting (other than Board of Directors)
Audit Committee	09-Nov-2022	-	Yes	6	6	4	0
Audit Committee		13-Feb-2023	Yes	6	6	3	0
Risk Management Committee		30-Jan-2023	Yes	3	3	2	0
Stakeholders Relationship Committee		02-Feb-2023	Yes	3	3	2	0
Nomination & Remuneration Committee		02-Feb-2023	Yes	4	4	3	0
Nomination & Remuneration Committee		25-Mar-2023	Yes	4	4	3	0
Maximum gap between any two consecutive (in number of days) [Only for Audit Committee]		95					

Related Party Transactions		
<i>Subject</i>	<i>Compliance status (Yes/No/NA)</i>	<i>Remark</i>
Whether prior approval of audit committee obtained	Yes	
Whether shareholder approval obtained for material RPT	Not Applicable	
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes	

Annexure 1

Sr. No.	Particulars	Yes/No
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee b. Nomination & remuneration committee c. Stakeholders relationship committee d. Risk management committee (applicable to the top 100 listed entities)	
3	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	
4	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	
5	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	
6	comments/observations/advice of Board of Directors may be mentioned here:	NIL

ANNEXURE II

Format to be submitted by listed entity at the end of the financial year (for the whole of financial year)

I. Disclosure on website in terms of Listing Regulations			
<i>Item</i>	<i>Compliance status (Yes/No/NA)</i>	<i>Company Remark</i>	<i>Website</i>
As per regulation 46(2) of the LODR:			
Details of business	Yes		https://krsnaadiagnostics.com/
Terms and conditions of appointment of independent directors	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2021/05/Terms-of-Appointment-of-Independent-Directors.pdf
Composition of various committees of board of directors	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2022/07/Composition-of-Board-and-Committees.pdf
Code of conduct of board of directors and senior	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2021/05/Code-of-Conduct.pdf
Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2022/02/Whistle-Blower-Policy.pdf
Criteria of making payments to non-executive directors	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2021/05/Criteria-for-making-Payments-to-Non-Executive-Directors.pdf
Policy on dealing with related party transactions	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2022/07/Policy-on-Related-Party-Transactions.pdf
Policy for determining 'material' subsidiaries	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2021/05/Policy-on-Material-Subsidiary.pdf
Details of familiarization programs imparted to independent directors	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2022/07/Familiarisation-Programme-for-Independent-Directors.pdf
Email address for grievance redressal and other relevant details entity who are responsible for assisting	Yes		https://krsnaadiagnostics.com/investors/

Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances other relevant details	Yes		https://krsnaadiagnostics.com/investors/
Financial results	Yes		https://krsnaadiagnostics.com/investors/#acceluidc09068d23
Shareholding pattern	Yes		https://krsnaadiagnostics.com/investors/#acceluidc09068d23
Details of agreements entered into with the media companies and/or their associates	Not Applicable		Not Applicable
Schedule of analyst or institutional investor meet and presentations made by the listed entity to analysts or institutional investors simultaneously with submission to stock exchange	Yes		https://krsnaadiagnostics.com/investors/#acceluidc09068d21
New name and the old name of the listed entity	Yes		https://krsnaadiagnostics.com/
Advertisements as per regulation 47 (1)	Yes		https://krsnaadiagnostics.com/investors/#acceluidc09068d21
Credit rating or revision in credit rating obtained by the entity for all its outstanding instruments obtained	Yes		https://krsnaadiagnostics.com/investors/#acceluid1691d0ed5
Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes		https://krsnaadiagnostics.com/investors/#acceluidfb9df0951
As per other regulations of the LODR:			
Whether company has provided information under separate section on its website as per Regulation 46(2)	Yes		https://krsnaadiagnostics.com/
Materiality Policy as per Regulation 30	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2021/06/Materiality-Policies.pdf
Dividend Distribution policy as per Regulation 43A (as applicable)	Yes		https://krsnaadiagnostics.com/wp-content/uploads/2021/06/Dividend-Distribution-Policy.pdf
It is certified that these contents on the website of the listed entity are correct.	Yes		https://krsnaadiagnostics.com/

II Annual Affirmations			
<i>Particulars</i>	<i>Regulation Number</i>	<i>Compliance status (Yes/No/NA)</i>	Company Remark
Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b) & 25(6)	Yes	
Board composition	17(1), 17(1A) & 17(1B)	Yes	
Meeting of Board of directors	17(2)	Yes	
Quorum of Board meeting	17(2A)	Yes	
Review of Compliance Reports	17(3)	Yes	
Plans for orderly succession for appointments	17(4)	Yes	
Code of Conduct	17(5)	Yes	
Fees/compensation	17(6)	Yes	
Minimum Information	17(7)	Yes	
Compliance Certificate	17(8)	Yes	
Risk Assessment & Management	17(9)	Yes	
Performance Evaluation of Independent Directors	17(10)	Yes	
Recommendation of Board	17(11)	Yes	
Maximum number of directorship	17A	Yes	
Composition of Audit Committee	18(1)	Yes	
Meeting of Audit Committee	18(2)	Yes	
Composition of nomination & remuneration committee	19(1) & (2)	Yes	
Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
Meeting of nomination & remuneration committee	19(3A)	Yes	
Composition of Stakeholder Relationship Committee	20(1), 20(2) and 20(2A)	Yes	
Meeting of stakeholder relationship committee	20(3A)	Yes	
Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	

Meeting of Risk Management Committee	21(3A)	Yes	
Vigil Mechanism	22	Yes	
Policy for related party Transaction	23(1),(1A),(5),(6),(7) & (8)	Yes	
Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
Approval for material related party transactions	23(4)	Not Applicable	
Disclosure of related party transactions on consolidated basis	23(9)	Yes	
Composition of Board of Directors of unlisted material Subsidiary	24(1)	Not Applicable	
Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes	
Annual Secretarial Compliance Report	24(A)	Yes	
Alternate Director to Independent Director	25(1)	Not Applicable	
Maximum Tenure	25(2)	Yes	
Meeting of independent directors	25(3) & (4)	Yes	
Familiarization of independent directors	25(7)	Yes	
Declaration from Independent Director	25(8) & (9)	Yes	
D & O Insurance for Independent Directors	25(10)	Yes	
Memberships in Committees	26(1)	Yes	
Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
Disclosure of Shareholding by Non- Executive Directors	26(4)	Yes	
Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	